Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Director departure
|
|
Alkermes plc. (ALKS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/30/2019 |
GN
| Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis |
| 07/30/2019 |
GN
| Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis |
| 05/30/2019 |
GN
| New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis |
| 04/16/2019 |
GN
| Market Trends Toward New Normal in Granite Construction, Alkermes plc, Rexford Industrial Realty, Ultra Clean, Stellus Capital Investment, and Astronics — Emerging Consolidated Expectations, Analyst Ratings |
| 02/28/2019 |
GN
| Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 02/25/2019 |
GN
| CLASS ACTION UPDATE for YRIV, ALKS, MKL and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders |
| 02/25/2019 |
GN
| Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis |
| 02/24/2019 |
GN
| CLASS ACTION UPDATE for DNKEY, ALKS, ATVI and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders |
|
|